Literature DB >> 16940454

Serum aldosterone concentration and cardiovascular risk in women with polycystic ovarian syndrome.

Teresa Cascella1, Stefano Palomba, Libuse Tauchmanovà, Francesco Manguso, Sebastiano Di Biase, Donato Labella, Francesco Giallauria, Carlo Vigorito, Annamaria Colao, Gaetano Lombardi, Francesco Orio.   

Abstract

CONTEXT: Polycystic ovary syndrome (PCOS) is associated with early impairment of vascular structure and a low-grade chronic inflammation. Aldosterone is a well-recognized cardiovascular risk (CVR) factor and is related to inflammatory processes.
OBJECTIVE: Our objective was to investigate serum aldosterone levels in PCOS and correlate them to some CVR factors and early atherosclerotic markers. DESIGN AND
SETTING: A prospective baseline-controlled clinical study was conducted at the University "Federico II" of Naples School of Medicine (Naples, Italy). PATIENTS: Fifty PCOS women age- and body mass index-matched with 50 healthy women were enrolled. MEAN OUTCOME MEASURES: Anthropometric, hormonal, and metabolic patterns, including plasma aldosterone, renin, and C-reactive protein, were measured in each subject. Intima-media thickness was also evaluated in each patient and control.
RESULTS: Aldosterone levels were significantly increased (P < 0.001) in PCOS compared with healthy women (10.5 +/- 3.2 vs. 5.7 +/- 2.5 ng/dl). In PCOS, a significant (P < 0.001) direct correlation between plasma aldosterone and homeostasis model assessment, C-reactive protein, intima-media thickness, and mean blood pressure was found. On the other hand, high-density lipoprotein cholesterol and potassium were inversely (P < 0.001) related to serum aldosterone. Multiple linear regression analysis showed that the area under the curve for insulin and homeostasis model assessment was linearly related to aldosterone in PCOS.
CONCLUSION: PCOS women show an insulin resistance related increase in serum aldosterone levels.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16940454     DOI: 10.1210/jc.2006-0399

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  27 in total

1.  Dihydrotestosterone stimulates aldosterone secretion by H295R human adrenocortical cells.

Authors:  Licy L Yanes; Damian G Romero
Journal:  Mol Cell Endocrinol       Date:  2009-01-21       Impact factor: 4.102

Review 2.  Management of primary aldosteronism and mineralocorticoid receptor-associated hypertension.

Authors:  Satoshi Morimoto; Atsuhiro Ichihara
Journal:  Hypertens Res       Date:  2020-05-18       Impact factor: 3.872

Review 3.  Third-generation Mineralocorticoid Receptor Antagonists: Why Do We Need a Fourth?

Authors:  Elise P Gomez-Sanchez
Journal:  J Cardiovasc Pharmacol       Date:  2016-01       Impact factor: 3.105

Review 4.  Carotid artery intima-media thickness in polycystic ovary syndrome: a systematic review and meta-analysis.

Authors:  Michelle L Meyer; Angela M Malek; Robert A Wild; Mary T Korytkowski; Evelyn O Talbott
Journal:  Hum Reprod Update       Date:  2011-11-22       Impact factor: 15.610

Review 5.  Cardiometabolic aspects of the polycystic ovary syndrome.

Authors:  Harpal S Randeva; Bee K Tan; Martin O Weickert; Konstantinos Lois; John E Nestler; Naveed Sattar; Hendrik Lehnert
Journal:  Endocr Rev       Date:  2012-07-24       Impact factor: 19.871

Review 6.  Circulating inflammatory markers in polycystic ovary syndrome: a systematic review and metaanalysis.

Authors:  Héctor F Escobar-Morreale; Manuel Luque-Ramírez; Frank González
Journal:  Fertil Steril       Date:  2010-12-17       Impact factor: 7.329

7.  Familial aggregation of circulating C-reactive protein in polycystic ovary syndrome.

Authors:  Arunachalam Sasidevi; Priyathama Vellanki; Allen R Kunselman; Nazia Raja-Khan; Andrea Dunaif; Richard S Legro
Journal:  Hum Reprod       Date:  2012-12-20       Impact factor: 6.918

Review 8.  The role of TGF-β in polycystic ovary syndrome.

Authors:  Nazia Raja-Khan; Margrit Urbanek; Raymond J Rodgers; Richard S Legro
Journal:  Reprod Sci       Date:  2013-04-12       Impact factor: 3.060

9.  Novel inflammatory markers in overweight women with and without polycystic ovary syndrome and following pharmacological intervention.

Authors:  L J Moran; C Meyer; S K Hutchison; S Zoungas; H J Teede
Journal:  J Endocrinol Invest       Date:  2009-10-15       Impact factor: 4.256

Review 10.  Developmental programming of cardiovascular disorders: focus on hypertension.

Authors:  Sheba M J MohanKumar; Andrew King; Andrew C Shin; Madhu P Sirivelu; P S MohanKumar; Gregory D Fink
Journal:  Rev Endocr Metab Disord       Date:  2007-08-01       Impact factor: 6.514

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.